As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
But while attendees never knew whether they’d be walking out into torrential rain or mild sunshine, they seemed far more confident in forecasting the climate for the sector next year.
Dealmaking was an obvious conversation starter, with the first day of the conference coinciding with Johnson & Johnson announcing a $2.2 billion acquisition of Ollin Biosciences and its potential rival to Roche’s blockbuster eye disease drug Vabysmo. Not to be outdone, Eli Lilly paid $1.5 billion for myelofibrosis biotech Calytrix Bio and followed that up Tuesday with a $5.9 billion oncology pact with Stipple Bio.
“I think it's a very healthy sector, and I expect M&A will just continue,” Jane Hobson, a partner at Baker McKenzie’s London M&A group, told Fierce over a coffee on the first day of the conference.
“I think we've had some very big deals,” Hobson added. “There's some mid-market and lower-end mid-market deals that should be coming through.”
While Hobson is always careful to avoid dropping clues about the exact deals she’s involved with, she was happy to predict that 2027 will be a “very busy year.”
Pharma companies’ approach to these bolt-on acquisitions takes two forms, Hobson pointed out. They are either looking for revenue that can boost their “bottom line straight away” or “still filling the[ir] innovation pipeline.”
“You’ve then got private equity, who are still keen to invest and expanding more into more risky investments,” she said.
Investors were also making headlines during the conference, with life sciences venture capital firm Sofinnova Partners announcing Monday that it had raised its biggest-ever fund at $815 million. The firm plans to invest the money in approximately 15 clinical-stage companies, primarily in Europe.
During a panel hosted by Fierce at the iconic Savoy Hotel as part of London Life Sciences Week, Antoine Papiernik, chairperson and managing partner at Sofinnova, made the bold prediction that next year will be “Europe’s time to shine.”
But realizing that potential will require a shift in mindset as European biopharma investors work to overcome their reputation for being more cautious than their U.S. counterparts.
While there is money in Europe, it is “just not being deployed in our field,” Papiernik explained to Fierce’s panel. “In Europe, we call it ‘capital risk,’ not venture capital. So the name is on it—this is risky!”
Another firm going big in Europe is Forbion, which unveiled last month a “landmark” 2.3 billion euro ($2.6 billion) fundraise across two life sciences-focused funds.
Wouter Joustra, a general partner at Forbion, told Fierce that the mammoth fundraise was an effort to provide European biotechs with the capital needed to sustain their growth for longer.
“Traditionally what we have been seeing is that there is absolutely no lack of ideas or science [in Europe], but there has been a lack of capital,” Joustra said. “That was also the opportunity for us to launch that fund.”
Government-backed initiatives across Europe have helped address that funding gap, but much of the support has been directed toward early-stage companies, Joustra explained. As a result, biotechs seeking larger, later-stage financing rounds have often had to turn to U.S. investors with deeper pockets.
“That is changing,” Joustra said. “So I think now with the pockets that these groups have in Europe, we are able to fund these companies for much longer.”
Still, when it comes to going public, all eyes remain on the U.S., because there’s “not yet a Nasdaq equivalent in Europe,” according to Joustra.
Papiernik echoed that sentiment during Fierce’s panel, arguing that Nasdaq remains “the only game in town, period.”
Indeed, optimistic predictions of an IPO revival on London’s struggling stock market have yet to materialize this year, although Reuters reported Wednesday that British cancer drug developer Ellipses Pharma was considering a London listing.
For U.S.-based investor Richard Lau, managing director at Foresite Capital, 2026 was “definitely a good year for us and for the broader kind of biotech market.”
Lau pointed to the SPDR S&P Biotech ETF (XBI), an exchange-traded fund that tracks the U.S. biotech sector, as a measure of the industry's health. The fund “cratered” to nearly $70 in spring 2025 before climbing to around $140 this year. More recently, it has “kind of plateaued,” Lau said, attributing the slowdown to a combination of rising interest rates and “a lot of stuff happening out in China.”
The rapid growth of China as a leading source of biopharma innovation and dealmaking was, unsurprisingly, a recurrent theme of the conference. Lau and his colleagues have first-hand experience, having traveled to Shanghai a couple of weeks earlier.
Understanding developments in China is increasingly important for U.S. investors because of the country's growing influence on the competitive landscape, Lau said.
China's biotech ecosystem has expanded rapidly over the past five years, he added, pointing to the country's clinical trial infrastructure as one example.
“They just have so many patients going through, and they have these automated bio banks to collect patient samples,” Lau explained. “They have it running 24/7 with robots that handle it. Compounding oncology drugs is a real bottleneck in clinical trials, and they have it all automated.”
The biggest uncertainty when it comes to China is whether the U.S. Treasury’s proposals to add “pharmaceutical compounds” to the Comprehensive Outbound Investment National Security (COINS) Act could freeze investments and dealmaking from U.S. companies.
“You're going to see more talk about that, and I think you're going to see a lot of U.S. funds pushing back against it,” Lau predicted.
Ahead of the Treasury Department’s final decision next year, Lau suggested that companies are wasting no time hedging their bets.
“I think you're going to see a lot of deals out of China between now and March, just trying to get into that window,” he added. “We’ve heard a lot of pharma have been set up there for like the last nine months, just looking at every single asset for deals.”
In recent weeks, investors have warned Fierce that clamping down on U.S. companies’ abilities to do business with China will only offer an opportunity for European biopharmas to swoop in and clean up the R&D riches.
But Forbion’s Joustra cautioned that avoiding the proposed COINS Act restrictions may not be so straightforward.
“If you, as a European fund, have U.S. partners in your investment committee or a U.S. office, it also applies,” he said.
Even European funds with no U.S. exposure could face complications when seeking follow-on financing or pursuing a Nasdaq listing, Joustra explained.
‘You see how it’s growing’
While the ultimate impact of the proposals remains uncertain, one aspect of the Jefferies conference, the centerpiece of London Life Sciences Week, was as familiar as ever. Attendees arriving Monday once again faced a long line in the cold outside the Waldorf Hilton hotel as organizers worked to accommodate the growing crowd.
“This is insane—I have a meeting at half past,” one biotech executive told Fierce as he sized up the line for registration after flying in from New York. Luckily, both of us were safely in the warm, if cramped, confines of the Waldorf within 20 minutes.
Having cemented its reputation last year as a worthy precursor to January's J.P. Morgan Healthcare Conference, the four-day gathering in London's theater district has become a must-attend event on the biopharma calendar, according to attendees who spoke with Fierce.
Baker McKenzie's Hobson compared the gathering to J.P. Morgan's annual conference in San Francisco, noting that both offer opportunities to reconnect with clients, catch up on industry developments and meet with business development teams. The key difference, she said, is the greater concentration of European attendees in London.
With London just a 45-minute flight from Forbion’s central base of Amsterdam, Joustra said his firm has a “soft spot” for the conference.
He described the London gathering as a preview of January’s J.P. Morgan Healthcare Conference, drawing a similarly broad mix of investors and companies.
“I think in terms of investors and companies, everyone is here, I would say, including a lot of the American groups with their senior people. Pharma is all over as well,” he added.
For Foresite’s Lau, this week marked his first time at the event, and he was struck by its size and the number of pharmaceutical business development teams in attendance.
While the London gathering has yet to reach the scale of J.P. Morgan, Lau said some companies are considering dividing their teams between the two conferences rather than sending everyone to both.
“They actually might start splitting up the two conferences and send some people to one and some people to another, based on geography or based on the type of deals they might want to do,” he said.